Abhijit Debnath

Scopus Publications

Advances in 11-HSD1 Inhibitor Development for Addressing Insulin Resistance and Beta-Cell Dysfunction in Type 2 diabetes mellitus
Pallavi Joshi, Avijit Mazumder, Bhavani Pentela, Abhijit Debnath
Journal of Pharmaceutical Innovation, 2026
Digoxin as a PD-1 Inhibitor: In Silico Analysis, NMR Characterization, Cytotoxicity Evaluation, and Glycerosome-Mediated Delivery for Enhanced Skin Cancer Therapy
Neha Sharma, Rupa Mazumder, Pallavi Rai, Abhijit Debnath
Journal of Pharmaceutical Innovation, 2026
In search of novel PD1 inhibitor from natural products by high-throughput virtual screening and molecular dynamics simulation
Neha Sharma, Abhijit Debnath, Rupa Mazumder, Pallavi Rai, Rajesh Kumar Singh
Plos One, 2026
Squamous cell carcinoma (SCC) represents a significant oncological challenge. While immune checkpoint inhibitors targeting PD-1/PD-L1 have revolutionized the treatment of SCC, current monoclonal antibody approaches face limitations, including poor tissue penetration, high costs, and immune-related adverse events in patients. Most existing small-molecule efforts target PD-L1, leaving PD-1/PD-L2 interactions intact and enabling immune escape. This study represents the first systematic identification of natural product-derived direct PD-1 inhibitors, offering broader pathway blockade compared to PD-L1-selective approaches. While current therapeutic limitations highlight the need for alternative methods, this computational study lays a foundation for experimental validation and potential advancement of a drug development pipeline. Through integrated computational screening of 17,967 phytochemicals from the IMPPAT database, we employed consensus molecular docking across seven algorithms, 300-ns molecular dynamics simulations, density functional theory calculations, and comprehensive ADME profiling. IMPHY004834 (Mahuannin D) from Ephedra sinica emerged as a lead compound with exceptional free binding energy, forming stable interactions with key PD-1. Molecular dynamics analysis revealed remarkable stability with consistent RMSD, lowest RMSF, and sustained hydrogen bonding throughout the simulation. The biflavonoid structure exhibits a favorable HOMO-LUMO gap, indicating chemical stability, while ADME profiling confirms drug-like properties, albeit requiring parenteral administration due to low GI absorption. This work establishes the first evidence for Mahuannin D’s PD-1 inhibitory mechanism, which was previously known only for its cytotoxic effects. It provides a validated computational framework for discovering natural product-based immune checkpoint inhibitors with superior pathway coverage compared to existing PD-L1-selective therapeutics.
Hydrogel-enabled drug delivery for ulcerative colitis
Mohit Sharma, Rupa Mazumder, Abhijit Debnath
Inflammopharmacology, 2026
Letter to the Editor: "Effectiveness of prophylactic push-dose vasopressors for preventing arterial hypotension during elective orotracheal intubation: A systematic review and meta-analysis"
Abhijit Debnath, Akanksha Bhatt, Nivedita Nikhil Desai, Hariharan Srinivasan
Journal of Critical Care, 2026
Predictive Analytics for Disease Prevention and Early Detection
Abhijit Debnath, Shalini Sharma, Sunil Kumar Tailor
Artificial Intelligence in Smart Healthcare Systems, 2026
Predictive analytics has emerged as a transformative force in modern healthcare, leveraging advanced computational methods and multi-modal data integration to revolutionize disease prevention and early detection. The convergence of artificial intelligence, machine learning algorithms, and sophisticated data analytics has enabled a paradigm shift from reactive to proactive medical interventions. This systematic analysis explores the fundamental predictive modeling approaches, including regression models, classification algorithms, and clustering techniques, which have demonstrated remarkable efficacy in disease prediction and risk stratification. The technological foundations incorporating artificial intelligence, big data infrastructure, and molecular-level analytics have achieved high prediction accuracies across various clinical applications. The investigation highlights substantial advancements in early disease detection through the synergistic integration of genomic markers, proteomic biomarkers, and metabolomics. Implementation of these technologies has yielded quantifiable improvements, including a reduction in hospital readmissions, decrease in emergency department utilization, and enhancement in chronic disease management outcomes. Emerging technologies, including quantum computing applications, edge computing implementations, and federated learning frameworks, show promise in further enhancing predictive capabilities while addressing critical challenges in data privacy, security, and clinical integration. The study emphasizes the significance of robust validation frameworks, ethical considerations, and standardized implementation protocols for successful clinical adoption. This comprehensive analysis provides evidence-based insights for healthcare professionals, researchers, and policymakers working to advance the implementation of predictive analytics in clinical practice.
Transferosomes: A Vesicular Tool for Transdermal Drug Delivery
Arpita Dua, Rupa Mazumder, Abhijit Debnath, Rakhi Mishra
Current Pharmaceutical Design, 2026
Innovative lipid-based vesicles called transferosomes are designed to improve the delivery of transdermal medications. These ultra-deformable vesicles, comprised of phospholipids and edge activators, can successfully pass through the skin’s stratum corneum and overcome conventional obstacles, resulting in better absorption of medications. Transferosomes have potential uses in treating several illnesses, such as cancer, and various skin ailments, and for vaccine delivery. They are also used to improve the bioavailability of poorly absorbed oral medications. Despite wide applications, the transferosomes formulation approach has limitations in scalability, stability, regulatory approval, and patient compliance, which must be addressed in ongoing and future research to maximize their therapeutic applications and establish transferosomes as a breakthrough in non-invasive drug delivery technology. This review covers the technical aspects involving the composition, structure, mechanisms of action, and formulation approach of transferosomes with comparison to other approaches, which will surely be beneficial for exploring novel targeted approaches involving liposomes, niosomes, ethosomes, and pharmacosomes.
Novel Approaches in Transdermal Delivery of Antidiabetic Bioactives – A Current Update
Arpita Dua, Rupa Mazumder, Abhijit Debnath, Anjna Rani
Drug Delivery Letters, 2026
Diabetes mellitus remains a significant worldwide health concern, demanding the development of more efficient, patient-friendly treatment approaches. By increasing drug absorption and enhancing patient compliance while reducing systemic side effects, an alternative to oral and injectable drugs that is non-invasive is provided by transdermal drug delivery systems. Current developments in the production of antidiabetic transdermal patches employing natural bioactive substances extracted from therapeutic plants are examined in this review. The molecular functions of phytochemicals, including polyphenols, alkaloids, and terpenoids, in glycemic control are highlighted, as is the development of patch designs using both traditional and cuttingedge fabrication methods, such as microneedles, electrospinning, and 3D printing. Additionally, the potential of smart technologies and nanocarrier systems, like liposomes, phytosomes, and ethosomes, integrated into patch matrices to enhance medication delivery and therapeutic results is emphasized. Recent patents and experimental prototypes demonstrate the translational significance of these inventions. The synergistic potential of enhanced TDDS and natural bioactives in revolutionizing diabetic care is thoroughly examined in this research, which also calls for additional clinical validation and interdisciplinary cooperation.
PTP1B Inhibitors for Type 2 Diabetes: From Natural Products, Synthetic Inhibitors, and Multi-Target Drug Design Strategies to Clinical Translation
Pallavi Joshi, Avijit Mazumder, Bhavani Pentela, Abhijit Debnath
Current Drug Targets, 2026
Introduction: Type 2 Diabetes Mellitus (T2DM) still exists as a worldwide health problem, and the current therapeutic options have selectivity and bioavailability issues. Protein Tyrosine Phosphatase 1B (PTP1B) emerged as an important therapeutic target for T2DM. Methods: In this study, we analyzed all publications between 2021 and 2025 available in the Scopus database, and the search was limited to English-language articles that were also indexed in PubMed. The search strategy employed multiple keyword combinations, including "PTP1B" OR "Protein Tyrosine Phosphatase 1B" OR "PTPN1", combined with inhibitor, drug discovery, type 2 diabetes, insulin resistance, and structural biology terms. Results: Natural products from plant, marine, and microbial sources demonstrate diverse PTP1B inhibitory mechanisms through their active compounds, which include terpenoids, flavonoids, alkaloids, and diarylheptanoids. The development of synthetic approaches that combine thiazole derivatives with coumarin-based compounds and peptide inhibitors has produced promising scaffolds. The researchers used computational methods to find new allosteric binding sites through molecular docking and molecular dynamics simulations. The four clinical candidates Ertirprotafib, Trodusquemine, ISIS-113715, and JTT-551 all failed because their selectivity and efficacy were insufficient, but the dual PTPN2/PTPN1 inhibitor ABBV-CLS-484 shows oncology treatment potential. Discussion: Beyond diabetes, PTP1B inhibition shows medical value for cancer immunotherapy treatment, together with neurodegenerative disorders, inflammation, and cardiovascular diseases. The development of PROTAC degraders, glycosylation-lipidation modifications, and multi-target inhibitors represents a new approach to solving past problems. Conclusion: The development of PTP1B inhibitors requires integrated approaches that include allosteric modulation, tissue-specific delivery, and patient stratification to achieve successful clinical translation across multiple disease indications.
Identification of natural product-based S6K1 inhibitor by high-throughput virtual screening
Siddhant, Abhijit Debnath, Salahuddin, Siddharth, Rajesh Kumar Singh
Letters in Drug Design and Discovery, 2026
Unveiling Targeted Approaches to Combat Drug Resistance in Cancer Chemotherapy
Siddharth ., Siddhant ., Salahuddin ., Avijit Mazumder, Rajnish Kumar, Abhijit Debnath
Current Pharmaceutical Design, 2026
Novel Drug Molecules for Atherosclerosis from Ginkgo biloba, an Endangered Himalayan Herb, via Pharmacoinformatics Approaches
Shiwani Chahal, Abhijit Debnath, Pooja Ridhal, Rajesh Kumar Singh, Akhilesh Mishra, Priyanka Siwach
Current Pharmaceutical Biotechnology, 2026
Molecular Insights and Therapeutic Innovations in Cervical Cancer: Emerging Drug Targets
Abhijit Debnath, Rajesh Kumar Singh, Rupa Mazumder, Arpita Dua, Pankaj Kumar Tyagi, Anil Kumar Singh
Advances in Pharmacological and Pharmaceutical Sciences, 2026
Targeting Undruggable Proteins: The siRNA Revolution Beyond Small Molecules - Advances, Challenges, and Future Prospects in Therapeutic Innovation
Sk Ashif Jan, Abhijit Debnath, Rajesh Kumar Singh, Pankaj Kumar Tyagi, Sachin Singh, Anil Kumar Singh
Current Gene Therapy, 2026
An Insight into the Structural Modification and Mechanism of Ursolic Acid at C-3 and C-28: Strategy for Searching Anti-Cancer Therapeutics
Divya Pratap Rav, Saurabh Kumar, Salahuddin, Rajnish Kumar, Avijit Mazumder, Abhijit Debnath, Siddharth, Pooja Kumari
Current Topics in Medicinal Chemistry, 2026
Histone modifications in biological age determination: mechanisms, biomarkers, and therapeutic perspectives
Anjali Tripathi, Garima Sharma, Vinay Kumar Pandey, Sarvesh Rustagi, Ashish Ranjan Sharma, Meenakshi Jha, Abhijit Debnath, Jomon George Joy, Jin-Chul Kim, Abhimanyu Kumar Jha
Geroscience, 2026
Discovery of Novel PTP1B Inhibitors by High-throughput Virtual Screening
Abhijit Debnath, Anjna Rani, Rupa Mazumder, Avijit Mazumder, Rajesh Kumar Singh, Shalini Sharma, Shikha Srivastava, Hema Chaudhary, Rashmi Mishra, Navneet Khurana, Jahanvi Sanchitra, Sk Ashif Jan
Current Computer Aided Drug Design, 2026
Correction to: Discovery of novel HBV core protein inhibitors by high throughput virtual screening (Scientific Reports, (2025), 15, 1, (13054), 10.1038/s41598-025-97242-6)
Jahanvi Sanchitra, Abhijit Debnath, Anil kumar Singh, Abhimanyu Kumar Jha, Rajesh Kumar Singh
Scientific Reports, 2025
Discovery of novel HBV core protein inhibitors by high throughput virtual screening
Jahanvi Sanchitra, Abhijit Debnath, Anil kumar Singh, Abhimanyu Kumar Jha, Rajesh Kumar Singh
Scientific Reports, 2025
Unlocking the antimalarial potential of novel steroid-tetraoxane hybrids through consensus molecular docking and molecular dynamics investigation
Dipankar Nath, Abhijit Debnath, Malita Sarma, Rajesh Kumar Singh, Dipak Chetia
Scientific Reports, 2025
Antihypertensive potential of diosgenin: A comparative pharmacoinformatics study
Shiwani Chahal, Abhijit Debnath, Renu Kumari, Pooja Ridhal, Rajeev Kumar Sahoo, Bijesh Kumar Biswal, Akhilesh Mishra, Priyanka Siwach
Computers in Biology and Medicine, 2025
Corrigendum to “Design, synthesis, docking, DFT, and MD simulation studies of new piperazine, 1,3,4-oxadiazole, and quinoline conjugates: A search for potent antiepileptic agents” [Bioorg. Chem. 162 (2025) 108595] (Bioorganic Chemistry (2025) 162, (S0045206825004754), (10.1016/j.bioorg.2025.108595))
Shrishti Tripathi, Rajnish Kumar, Abhijit Debnath, Himanshu Singh, Ranjeet Kumar Yadav, Salahuddin
Bioorganic Chemistry, 2025
Design, synthesis, docking, DFT, and MD simulation studies of new piperazine, 1,3,4-oxadiazole, and quinoline conjugates: A search for potent antiepileptic agents
Shrishti Tripathi, Rajnish Kumar, Abhijit Debnath, Himanshu Singh, Ranjeet Kumar Yadav, Salahuddin
Bioorganic Chemistry, 2025
Integration of In-vivo screening, molecular docking, and molecular dynamics simulations for studying the antiepileptic potential of newly synthesized 5-naphthalen-1-yl-5,10-dihydro-1H-pyrimido[4,5-b]quinoline-2,4-diones in optimized reaction conditions by utilizing L-proline as green catalyst
Rajnish Kumar, Himanshu Singh, Abhijit Debnath, Salahuddin, Avijit Mazumder, N. Bano, Virat Khanna, Sorabh Lakhanpal, Manikonda Srinivasa Sesha Sai, Ganesh Bushi, Shilpa Gaidhane, Pankaj Kumar Tyagi, Bhupinder Kapoor
Journal of Molecular Structure, 2025
Experimental, quantum chemical spectroscopic investigation, topological, molecular docking/dynamics and biological assessment studies of 2,6-Dihydroxy-4-methyl quinoline
Rakesh Chandra Joshi, Shahid Husain, Nupur Pandey, Nisha Fatma, Divya Bisen, Ratnakar Upadhyay, Abhijit Debnath, Sanjay Pant, Hirdyesh Mishra
Journal of Molecular Structure, 2025
Clinical Progress of Targeted Therapy for Breast Cancer: A Comprehensive Review
Abhijit Debnath, Rupa Mazumder
Current Cancer Drug Targets, 2025
Development of Transdermal Drug Delivery Approaches to Combat Diabetes: An Update
Priya Singhal, Rupa Mazumder, Anjna Rani, Abhijit Debnath
Current Drug Metabolism, 2025
Comment on “Effects of high-intensity interval training and moderate-intensity continuous training in coronary heart disease: A systematic review and meta-analysis”
A. Debnath, A. Bhatt, N. Nikhil Desai, H. Srinivasan
Science and Sports, 2025
Identification of novel cyclin-dependent kinase 4/6 inhibitors from marine natural products
Abhijit Debnath, Rupa Mazumder, Anil Kumar Singh, Rajesh Kumar Singh
Plos One, 2025
Exosome Engineering for Targeted Therapy: Tools and Techniques
Shalini Sharma, Anjali Mishra, Abhijit Debnath, Rajesh Kumar Singh
Current Drug Delivery, 2025
Emerging Multi-Target Therapies for Type 2 Diabetes: Bridging Drug Innovation and Precision Delivery
Priya Singhal, Rupa Mazumder, Anjna Rani, Abhijit Debnath
Current Topics in Medicinal Chemistry, 2025
Challenges and Progress of Orphan Drug Development for Rare Diseases
Abhijit Debnath, Rupa Mazumder, Avijit Mazumder, Pankaj Kumar Tyagi, Rajesh Kumar Singh
Current Pharmaceutical Biotechnology, 2025
A Critical Analysis of Biomarkers and Diagnostics Strategies for Alzheimer’s Syndrome
Sushmita Sil, Abhijit Debnath, Prakash S Surjya, Sahil Suri, Kamineni Sairam, Bhavuk Samrat
Health Leadership and Quality of Life, 2025
A Comprehensive Review on Promising Herbal Drug Discovery for Breast Cancer Management
Adwitiya Banerjee, Shivnath Banerjee, Anil Kumar Singh, Irina V. Gravel, Abhijit Debnath, Rajesh Kumar Singh
Current Medicinal Chemistry, 2025
Synthesis, anticonvulsant potential, and molecular docking studies of Schiff bases bearing 2’,6-dichloro-2,3’-biquinoline
Abhishek Shankar Sharma, Salahuddin Salahuddin, Kavita Rana, Abhijit Debnath, Avijit Mazumder, Rajnish Kumar, Mohamed Jawed Ahsan, Mohammad Shahar Yar, Pankaj Kumar Tyagi, Saurabh Singh
Indian Journal of Heterocyclic Chemistry, 2025
Quest for discovering novel CDK12 inhibitor
Abhijit Debnath, Rajesh Kumar Singh, Rupa Mazumder, Avijit Mazumder, Shikha Srivastava, Hema Chaudhary, Saloni Mangal, Jahanvi Sanchitra, Pankaj Kumar Tyagi, Sachin Kumar Singh, Anil Kumar Singh
Journal of Receptors and Signal Transduction, 2025
miRNA-Targeted Vaccines: A Promising Approach for Viral Attenuation and Immunogenicity Enhancement
Abhijit Debnath, Rupa Mazumder, Avijit Mazumder, Soumya Tripathi, Arpita Dua, Rajesh Kumar Singh, Saloni Mangal, Jahanvi Sanchitra, Pratibha Pandey, Biplab Pal, Hema Chaudhary, Parul Sharma, Shikha Srivastava
Current Gene Therapy, 2025
Advancements of Glucose Monitoring Biosensor: Current State, Generations of Technological Progress and Innovation Dynamics
Arpita Dua, Abhijit Debnath, Kunal Kumar, Rupa Mazumder, Avijit Mazumder, Rajesh Kumar Singh, Saloni Mangal, Jahanvi Sanchitra, Fahad Khan, Soumya Tripathi, Sukriti Vishwas, Hema Chaudhary, Parul Sharma, Shikha Srivastava
Current Pharmaceutical Biotechnology, 2025
Discovery of novel CDK4/6 inhibitors from fungal secondary metabolites
Abhijit Debnath, Rupa Mazumder, Rajesh Kumar Singh, Anil Kumar Singh
International Journal of Biological Macromolecules, 2024
Role of PD-1 in Skin Cancer: Molecular Mechanism, Clinical Applications, and Resistance
Neha Sharma, Rupa Mazumder, Pallavi Rai, Abhijit Debnath
Chemical Biology and Drug Design, 2024
Three-Dimensional Hydrogel Bioprinting Technology as a Scaffold of Novel Drug Delivery and Biomedical Devices: A Comprehensive Review
Mohhammad Ramzan, Mohammed Sabir, Sukhbir Singh, Abhijit Debnath
Bio Web of Conferences, 2024
Identification of Novel CDK 4/6 Inhibitors by High-throughput Virtual Screening
Abhijit Debnath, Rupa Mazumder
Letters in Drug Design and Discovery, 2024
In silico Identification of HDAC Inhibitors for Multiple Myeloma: A Structure-based Virtual Screening, Drug Likeness, ADMET Profiling, Molecular Docking, and Molecular Dynamics Simulation Study
Abhijit Debnath, Rupa Mazumder, Avijit Mazumder, Rajesh Singh, Shikha Srivastava
Letters in Drug Design and Discovery, 2024
A Deep Dive into PDE5 Inhibition: Innovative Discoveries via Virtual Screening
Abhijit Debnath, Hema Chaudhary, Parul Sharma, Rajesh Singh, Shikha Srivastava
Letters in Drug Design and Discovery, 2024
Molecular landscape of lung cancer: insights into therapeutic targets and clinical outcomes
Saloni Mangal, Abhijit Debnath, Rupa Mazumder, Avijit Mazumder, Rajesh Kumar Singh, Jahanvi Sanchitra, S.K. Asif Jan, Pratibha Pandey, Bimlesh Kumar, Anil Kumar Singh
All Life, 2024
In Search of Novel SGLT2 Inhibitors by High-throughput Virtual Screening
Abhijit Debnath, Shalini Sharma, Rupa Mazumder, Avijit Mazumder, Rajesh Singh, Ankit Kumar, Arpita Dua, Priya Singhal, Arvind Kumar, Gurvinder Singh
Current Drug Discovery Technologies, 2024
Potential of Azadirachta indica A. Juss., Eucalyptus globulus Labill. and Ocimum sanctum L. Phytochemicals as Herbal Hand Sanitizer: A Review
Pranay Jain, Rajesh Mishra, Abhijit Debnath, Mukesh C. Sharma
Allelopathy Journal, 2023
Discovery of Novel Cathepsin D Inhibitors by High-Throughput Virtual Screening
Biointerface Research in Applied Chemistry, 2023
PD 1: A Trending Target in Anti-cancer Research
Shweta Rani, Rupa Mazumder, Neha Sharma, Rakhi Mishra, Abhijit Debnath, et al.
Biointerface Research in Applied Chemistry, 2023
A Brief Study on Drug Repurposing: New Way of Boosting Drug Discovery
Rupa Mazumder, Kamal Kant Kaushik, Abhijit Debnath, Manisha Patel
Letters in Drug Design and Discovery, 2023
High-throughput virtual screening of novel CHK1 inhibitors
Onkologia I Radioterapia, 2023
A BRIEF DESCRIPTION OF COVID-19 PULMONARY VIRAL INFECTION AND REPURPOSING OF DRUGS FOR ITS TREATMENT
MANISHA PATEL, RUPA MAZUMDER, KAMAL KANT KAUSHIK, ABHIJIT DEBNATH, RAKHI MISHRA, SHUBHAM PAL
International Journal of Applied Pharmaceutics, 2022
IN-SILICO INVESTIGATION BASED PLANT SECONDARY METABOLITES AS PROMISING IMMUNOSTIMULANTS AGAINST COVID-19
Suranaree Journal of Science and Technology, 2022
Immune Checkpoint Inhibitors Targeting CTLA-4 in Cutaneous Malignancies: Recent Updates
International Journal of Drug Delivery Technology, 2022

RECENT SCHOLAR PUBLICATIONS

Advances in 11-HSD1 Inhibitor Development for Addressing Insulin Resistance and Beta-Cell Dysfunction in Type 2 diabetes mellitus
P Joshi, A Mazumder, B Pentela, A Debnath
Journal of Pharmaceutical Innovation 21 (4), 380 , 2026
2026
In search of novel PD1 inhibitor from natural products by high-throughput virtual screening and molecular dynamics simulation
N Sharma, A Debnath, R Mazumder, P Rai, RK Singh
PloS one 21 (4), e0339355 , 2026
2026
Digoxin as a PD-1 Inhibitor: In Silico Analysis, NMR Characterization, Cytotoxicity Evaluation, and Glycerosome-Mediated Delivery for Enhanced Skin Cancer Therapy
N Sharma, R Mazumder, P Rai, A Debnath
Journal of Pharmaceutical Innovation 21 (2), 155 , 2026
2026
Identification of natural product-based S6K1 inhibitor by high-throughput virtual screening
A Debnath, RK Singh
Letters in Drug Design & Discovery, 100358 , 2026
2026
Hydrogel-enabled drug delivery for ulcerative colitis: M. Sharma et al.
M Sharma, R Mazumder, A Debnath
Inflammopharmacology, 1-32 , 2026
2026
Histone modifications in biological age determination: mechanisms, biomarkers, and therapeutic perspectives
A Tripathi, G Sharma, VK Pandey, S Rustagi, AR Sharma, M Jha, ...
GeroScience, 1-19 , 2026
2026
Exosome Engineering for Targeted Therapy: Tools and Techniques
S Sharma, A Mishra, A Debnath, RK Singh
Current Drug Delivery , 2026
2026
Citations: 1
Emerging Multi-Target Therapies for Type 2 Diabetes: Bridging Drug Innovation and Precision Delivery
P Singhal, R Mazumder, A Rani, A Debnath
Current Topics in Medicinal Chemistry , 2026
2026
Molecular Insights and Therapeutic Innovations in Cervical Cancer: Emerging Drug Targets
A Debnath, RK Singh, R Mazumder, A Dua, PK Tyagi, AK Singh
Advances in Pharmacological and Pharmaceutical Sciences 2026 (1), 1452252 , 2026
2026
In Silico, In Vitro, and In Vivo Evaluation of Woodfordia Fruticosa for Cardio Protection against Doxorubicin‐Induced Cardiomyopathy
G Goyal, A Debnath, AK Pal, M Taleuzzaman, K Nagarajan, V Kumar
Chemistry & Biodiversity 23 (1), e02217 , 2026
2026
Novel Drug Molecules for Atherosclerosis from Ginkgo biloba, an Endangered Himalayan Herb, Via Pharmacoinformatics Approaches.
S Chahal, A Debnath, P Ridhal, RK Singh, A Mishra, P Siwach
Current Pharmaceutical Biotechnology , 2025
2025
Antihypertensive potential of diosgenin: A comparative pharmacoinformatics study
S Chahal, A Debnath, R Kumari, P Ridhal, RK Sahoo, BK Biswal, ...
Computers in Biology and Medicine 196, 110911 , 2025
2025
Citations: 2
Unlocking the antimalarial potential of novel steroid-tetraoxane hybrids through consensus molecular docking and molecular dynamics investigation
D Nath, A Debnath, M Sarma, RK Singh, D Chetia
Scientific Reports 15 (1), 30389 , 2025
2025
Citations: 1
Advancements of glucose monitoring biosensor: Current state, generations of technological progress and innovation dynamics
A Dua, A Debnath, K Kumar, R Mazumder, A Mazumder, RK Singh, ...
Current Pharmaceutical Biotechnology 26 (11), 1716-1733 , 2025
2025
Citations: 28
miRNA-Targeted vaccines: a Promising Approach for viral attenuation and immunogenicity enhancement
A Debnath, R Mazumder, A Mazumder, S Tripathi, A Dua, RK Singh, ...
Current Gene Therapy 25 (4), 360-373 , 2025
2025
Citations: 3
Design, synthesis, docking, DFT, and MD simulation studies of new piperazine, 1, 3, 4-oxadiazole, and quinoline conjugates: A search for potent antiepileptic agents
S Tripathi, R Kumar, A Debnath, H Singh, RK Yadav
Bioorganic Chemistry 162, 108595 , 2025
2025
Citations: 3
Clinical progress of targeted therapy for breast cancer: a comprehensive review
A Debnath, R Mazumder
Current Cancer Drug Targets 25 (6), 555-573 , 2025
2025
Citations: 12
Discovery of novel HBV core protein inhibitors by high throughput virtual screening
J Sanchitra, A Debnath, A Singh, AK Jha, RK Singh
Scientific Reports 15 (1), 13054 , 2025
2025
Citations: 3
Integration of In-vivo screening, molecular docking, and molecular dynamics simulations for studying the antiepileptic potential of newly synthesized 5-naphthalen-1-yl-5, 10 …
R Kumar, H Singh, A Debnath, A Mazumder, N Bano, V Khanna, ...
Journal of Molecular Structure 1324, 140814 , 2025
2025
Citations: 2
Experimental, quantum chemical spectroscopic investigation, topological, molecular docking/dynamics and biological assessment studies of 2, 6-Dihydroxy-4-methyl quinoline
RC Joshi, S Husain, N Pandey, N Fatma, D Bisen, R Upadhyay, ...
Journal of Molecular Structure 1321, 140123 , 2025
2025
Citations: 4

MOST CITED SCHOLAR PUBLICATIONS

Advancements of glucose monitoring biosensor: Current state, generations of technological progress and innovation dynamics
A Dua, A Debnath, K Kumar, R Mazumder, A Mazumder, RK Singh, ...
Current Pharmaceutical Biotechnology 26 (11), 1716-1733 , 2025
2025
Citations: 28
Targeting undruggable proteins: The siRNA revolution beyond small molecules-advances, challenges, and future prospects in therapeutic innovation
SKA Jan, A Debnath, RK Singh, PK Tyagi, S Singh, AK Singh
Current Gene Therapy , 2025
2025
Citations: 15
In silico Identification of HDAC Inhibitors for Multiple Myeloma: A Structure-based Virtual Screening, Drug Likeness, ADMET Profiling, Molecular Docking, and …
A Debnath, R Mazumder, A Mazumder, R Singh, S Srivastava
Letters in Drug Design & Discovery 21 (5), 961-978 , 2024
2024
Citations: 15
Clinical progress of targeted therapy for breast cancer: a comprehensive review
A Debnath, R Mazumder
Current Cancer Drug Targets 25 (6), 555-573 , 2025
2025
Citations: 12
A brief study on drug repurposing: new way of boosting drug discovery
KK Kaushik, R Mazumder, A Debnath, M Patel
Letters in Drug Design & Discovery 20 (3), 264-278 , 2023
2023
Citations: 12
Discovery of novel PTP1B inhibitors by High-throughput virtual screening
A Debnath, A Rani, R Mazumder, A Mazumder, RK Singh, S Sharma, ...
Current Computer-Aided Drug Design , 2024
2024
Citations: 11
Discovery of novel CDK4/6 inhibitors from fungal secondary metabolites
A Debnath, R Mazumder, RK Singh, AK Singh
International Journal of Biological Macromolecules 282, 136807 , 2024
2024
Citations: 9
Identification of novel cyclin-dependent kinase 4/6 inhibitors from marine natural products
A Debnath, R Mazumder, AK Singh, RK Singh
Plos one 20 (1), e0313830 , 2025
2025
Citations: 8
Challenges and progress of orphan drug development for rare diseases
A Debnath, R Mazumder, A Mazumder, PK Tyagi, RK Singh
Current Pharmaceutical Biotechnology , 2025
2025
Citations: 8
Identification of novel CDK 4/6 inhibitors by high-throughput virtual screening
A Debnath, R Mazumder
Letters in Drug Design & Discovery 21 (15), 3229-3246 , 2024
2024
Citations: 6
Role of PD‐1 in Skin Cancer: Molecular Mechanism, Clinical Applications, and Resistance
N Sharma, R Mazumder, P Rai, A Debnath
Chemical Biology & Drug Design 104 (3), e14613 , 2024
2024
Citations: 6
In search of novel SGLT2 inhibitors by high-throughput virtual screening
A Debnath, S Sharma, R Mazumder, A Mazumder, R Singh, A Kumar, ...
Current Drug Discovery Technologies 21 (3), 20-31 , 2024
2024
Citations: 5
Experimental, quantum chemical spectroscopic investigation, topological, molecular docking/dynamics and biological assessment studies of 2, 6-Dihydroxy-4-methyl quinoline
RC Joshi, S Husain, N Pandey, N Fatma, D Bisen, R Upadhyay, ...
Journal of Molecular Structure 1321, 140123 , 2025
2025
Citations: 4
Molecular landscape of lung cancer: insights into therapeutic targets and clinical outcomes
S Mangal, A Debnath, R Mazumder, A Mazumder, RK Singh, J Sanchitra, ...
All Life 17 (1), 2417192 , 2024
2024
Citations: 4
A brief description of COVID-19 pulmonary viral infection and repurposing of drugs for its treatment
M Patel, R Mazumder, KK Kaushik, A Debnath, R Mishra, S Pal
PATEL M, MAZUMDER R, KAUSHIK KK, DEBNATH A, MISHRA R, PAL S. A BRIEF … , 2022
2022
Citations: 4
miRNA-Targeted vaccines: a Promising Approach for viral attenuation and immunogenicity enhancement
A Debnath, R Mazumder, A Mazumder, S Tripathi, A Dua, RK Singh, ...
Current Gene Therapy 25 (4), 360-373 , 2025
2025
Citations: 3
Design, synthesis, docking, DFT, and MD simulation studies of new piperazine, 1, 3, 4-oxadiazole, and quinoline conjugates: A search for potent antiepileptic agents
S Tripathi, R Kumar, A Debnath, H Singh, RK Yadav
Bioorganic Chemistry 162, 108595 , 2025
2025
Citations: 3
Discovery of novel HBV core protein inhibitors by high throughput virtual screening
J Sanchitra, A Debnath, A Singh, AK Jha, RK Singh
Scientific Reports 15 (1), 13054 , 2025
2025
Citations: 3
A Deep Dive into PDE5 Inhibition: Innovative Discoveries via Virtual Screening
A Debnath, H Chaudhary, P Sharma, R Singh, S Srivastava
Letters in Drug Design & Discovery 21 (16), 3425-3442 , 2024
2024
Citations: 3
PD 1: A Trending Target in Anti-cancer Research
S Rani, R Mazumder, N Sharma, R Mishra, A Debnath, SD Paul
Biointerface Research in Applied Chemistry 13 (3), 218 , 2022
2022
Citations: 3

Abhijit Debnath

RESEARCH, TEACHING, or OTHER INTERESTS

Scopus Publications

RECENT SCHOLAR PUBLICATIONS

MOST CITED SCHOLAR PUBLICATIONS